Compare Eli Lilly And Co (LLY) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Oscar Health Inc — how do they compare? Eli Lilly And Co trades at $1,177.46 (market cap $1.04T), while Oscar Health Inc trades at $33.36 (market cap $10.22B). The key difference: Eli Lilly And Co is far larger — about 101.8× Oscar Health Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Oscar Health Inc for 15 Days on average.
| LLY | OSCR | |
|---|---|---|
Market Cap | $1.04T | $10.22B |
Volume | 3,064,878 | 4,123,394 |
Sector | Health | Health |
52-Week High | $1.28K | $33.81 |
52-Week Low | $799.57 | $10.85 |
Typical Hold Time | 93 Days | 15 Days |
Enterprise Value | $1.09T | $6.57B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
OSCR trades at $33.41, up 1.52% today, with a bullish technical signal and strong recent earnings beats in Q1 and Q2 2026. The stock shows robust revenue growth, with 2026 revenue projected at $15.3B and a return to profitability. Analyst sentiment is mixed but leans positive, with a consensus price target of $34.00. Recent news highlights market share gains and raised 2026 guidance, though the stock faces tests from rising medical costs.
The outlook is cautiously optimistic, driven by scalable growth in the ACA market and margin expansion opportunities. Key risks include medical cost pressures and competitive threats. Upside potential exists if the company executes on its 2029 EPS target of $4+, but investors should monitor profitability sustainability amid cost headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
